Altered kynurenine pathway metabolism in autism: Implication for immune‐induced glutamatergic activity
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Dysfunction of the serotoninergic and glutamatergic systems is implicated in the pathogenesis of autism spectrum disorder (ASD) together with various neuroinflammatory mediators. As the kynurenine pathway (KP) of tryptophan degradation is activated in neuroinflammatory states, we hypothesized that there may be a link between inflammation in ASD and enhanced KP activation resulting in reduced serotonin synthesis from tryptophan and production of KP metabolites capable of modulating glutamatergic activity. A cross‐sectional study of 15 different Omani families with newly diagnosed children with ASD (n = 15) and their age‐matched healthy siblings (n = 12) was designed. Immunological profile and the KP metabolic signature were characterized in the study participants. Our data indicated that there were alterations to the KP in ASD. Specifically, increased production of the downstream metabolite, quinolinic acid, which is capable of enhancing glutamatergic neurotransmission was noted. Correlation studies also demonstrated that the presence of inflammation induced KP activation in ASD. Until now, previous studies have failed to establish a link between inflammation, glutamatergic activity, and the KP. Our findings also suggest that increased quinolinic acid may be linked to 16p11.2 mutations leading to abnormal glutamatergic activity associated with ASD pathogenesis and may help rationalize the efficacy of sulforaphane treatment in ASD.Autism Res2016, 9: 621–631. © 2015 International Society for Autism Research, Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The anti-inflammatory effect of exercise
Petersen, A. M. W., & Pedersen, B. K. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00164.2004 · Cited by 3,100 · cited 1×
“Inflammation can be defined by a two to threefold increase in concentration of systemic inflammatory cytokines [Petersen and Pedersen, 2005].”
BackgroundModel of autism: increased ratio of excitation/inhibition in key neural systems
Rubenstein, J. L. R., & Merzenich, M. M. (2003) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2003.00037.x · Cited by 2,768 · cited 3×
“How excitatory/inhibitory amino acids may impact ASD has also attracted recent research focus, as imbalances in glutamate excitation or its inhibitory counterpart, gamma-aminobutyric acid (GABA) that may lead to hyperexcitation or excitotoxicity [Rubenstein & Merzenich, 2003].”
BackgroundResultInfluentialNeuroglial activation and neuroinflammation in the brain of patients with autism
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005) · Annals of Neurology · doi:10.1002/ana.20315 · Cited by 2,149
Association between Microdeletion and Microduplication at 16p11.2 and Autism
Weiss, L. A., Shen, Y., Korn, J. M., Arking, D. E., Miller, D. T., Fossdal, R., Saemundsen, E., Stefansson, H., Ferreira, M. A. R., Green, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075974 · Cited by 1,666
Elevated immune response in the brain of autistic patients
Li, X., Chauhan, A., Sheikh, A. M., Patil, S., Chauhan, V., Li, X.-M., Ji, L., Brown, T., & Malik, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.12.002 · Cited by 786
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 1×
“As QA is a known NMDA agonist capable of evoking excitatory signaling similar to glutamate [Stone and Perkins, 1981], increased QA in the brain may disrupt the excitation/inhibition ratio.”
BackgroundRecurrent 16p11.2 microdeletions in autism
Kumar, R. A., KaraMohamed, S., Sudi, J., Conrad, D. F., Brune, C., Badner, J. A., Gilliam, T. C., Nowak, N. J., Cook, E. H., Dobyns, W. B., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm376 · Cited by 731
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 1×
“However, arguing against this need are previous studies showing a good correlation between plasma and CSF levels of TRP, KYN, and QA in various diseases and species [Curzon, 1979; Raison et al., 2010; Young et al., 1975].”
ResultQuinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595 · cited 1×
“QA is an agonist of the N-methyl-D-aspartate (NMDA) receptor and a known endogenous excitotoxin [Guillemin, 2012].”
BackgroundSelf-citationSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568 · cited 4×
“Several previous studies have shown that KP metabolites kynurenic acid (KA) and quinolinic acid (QA) may be involved in several psychiatric disorders including schizophrenia and depression with suicidal ideation [Erhardt et al., 2013; Steiner et al., 2011; Sublette et al., 2011; Zavitsanou et al., 2014].”
BackgroundResultSelf-citationGuillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497
Self-citationSulforaphane treatment of autism spectrum disorder (ASD)
Singh, K., Connors, S. L., Macklin, E. A., Smith, K. D., Fahey, J. W., Talalay, P., & Zimmerman, A. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416940111 · Cited by 449
Rosenhall, U., Nordin, V., Sandström, M., Ahlsén, G., & Gillberg, C. (1999) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1023022709710 · Cited by 403
Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation?
MEYER, U., FELDON, J., & DAMMANN, O. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e318212c196 · Cited by 357
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345 · cited 1×
“…previous studies have shown that KP metabolites kynurenic acid (KA) and quinolinic acid (QA) may be involved in several psychiatric disorders including schizophrenia and depression with suicidal ideation [Erhardt et al., 2013; Steiner et al., 2011; Sublette et al., 2011; Zavitsanou et al., 2014].”
ResultSelf-citationDosage-dependent phenotypes in models of 16p11.2 lesions found in autism
Horev, G., Ellegood, J., Lerch, J. P., Son, Y.-E. E., Muthuswamy, L., Vogel, H., Krieger, A. M., Buja, A., Henkelman, R. M., Wigler, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114042108 · Cited by 330 · cited 1×
“2 has been strongly linked to ASD [Horev et al., 2011; Kumar et al., 2008; Weiss et al., 2008].”
BackgroundA 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders
Zufferey, F., Sherr, E. H., Beckmann, N. D., Hanson, E., Maillard, A. M., Hippolyte, L., Macé, A., Ferrari, C., Kutalik, Z., Andrieux, J., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101203 · Cited by 326 · cited 1×
“2 deletions evidenced frequent seizures [Zufferey et al., 2012].”
BackgroundEffects of tryptophan depletion in drug-free adults with autistic disorder
McDougle, C. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110029004 · Cited by 301
Cerebrospinal Fluid and Serum Markers of Inflammation in Autism
Zimmerman, A. W., Jyonouchi, H., Comi, A. M., Connors, S. L., Milstien, S., Varsou, A., & Heyes, M. P. (2005) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.03.014 · Cited by 300 · cited 1×
“Zimmerman et al. showed that both CSF QA and neopterin levels were lower in children with ASD than controls [Zimmerman et al., 2005].”
Backgroundde Bildt, A., Sytema, S., Ketelaars, C., Kraijer, D., Mulder, E., Volkmar, F., & Minderaa, R. (2004) · Journal of Autism and Developmental Disorders · doi:10.1023/b:jadd.0000022604.22374.5f · Cited by 278
Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder
Sublette, M. E., Galfalvy, H. C., Fuchs, D., Lapidus, M., Grunebaum, M. F., Oquendo, M. A., John Mann, J., & Postolache, T. T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.002 · Cited by 250 · cited 2×
“Several previous studies have shown that KP metabolites kynurenic acid (KA) and quinolinic acid (QA) may be involved in several psychiatric disorders including schizophrenia and depression with suicidal ideation [Erhardt et al., 2013; Steiner et al., 2011; Sublette et al., 2011; Zavitsanou et al., 2014].”
ResultSerotonin and dopamine transporter binding in children with autism determined by SPECT
Makkonen, I., Riikonen, R., Kokki, H., Airaksinen, M. M., & Kuikka, J. T. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.03027.x · Cited by 169
Ting, K. K., Brew, B. J., & Guillemin, G. J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-36 · Cited by 166
Self-citationQuinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α
PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149 · cited 8×
“This may imply that the pro-inflammatory response indicated by production of cytokines such as IFN-c, TNF-a, and IL-6 may be attenuated by IL-1ra and IL-10.”
BackgroundInfluentialZavitsanou, K., Lim, C. K., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S. D., Guillemin, G. J., & Weickert, C. S. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.05.011 · Cited by 46
Self-citation
Cited by
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Agus, A., Planchais, J., & Sokol, H. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.003 · Cited by 3,180
Bedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0428-y · Cited by 642
Golubeva, A. V., Joyce, S. A., Moloney, G., Burokas, A., Sherwin, E., Arboleya, S., Flynn, I., Khochanskiy, D., Moya-Pérez, A., Peterson, V., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.020 · Cited by 364
“Of note, recent evidence suggests altered 5-HT and kynurenine metabolism in ASD (Boccuto et al., 2013; Lim et al., 2015; Muller et al., 2016).”
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
Lim, C. K., Bilgin, A., Lovejoy, D. B., Tan, V., Bustamante, S., Taylor, B. V., Bessede, A., Brew, B. J., & Guillemin, G. J. (2017) · Scientific Reports · doi:10.1038/srep41473 · Cited by 255
Self-citation
Metadata
- Authors
- Lim, C. K., Essa, M. M., de Paula Martins, R., Lovejoy, D. B., Bilgin, A. A., Waly, M. I., Al‐Farsi, Y. M., Al‐Sharbati, M., Al‐Shaffae, M. A., & Guillemin, G. J.
- Venue
- Autism Research
- Publisher
- Wiley
- Published
- 2015-10-24
- Volume
- 9
- Issue
- 6
- Pages
- 621-631
- ISSN
- 1939-3792 (ISSN-L)
- 1939-3806
- OpenAlex
- W1837935334
- Cited by
- 102
- References
- 26
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.